Article
Hematology
Marina Lafage-Pochitaloff, Bastien Gerby, Veronique Baccini, Laetitia Largeaud, Vincent Fregona, Nais Prade, Pierre-Yves Juvin, Laura Jamrog, Pierre Bories, Sylvie Hebrard, Stephanie Lagarde, Veronique Mansat-De Mas, Oliver M. Dovey, Kosuke Yusa, George S. Vassiliou, Joop H. Jansen, Tobias Tekath, David Rombaut, Genevieve Ameye, Carole Barin, Audrey Bidet, John Boudjarane, Marie-Agnes Collonge-Rame, Carine Gervais, Antoine Ittel, Christine Lefebvre, Isabelle Luquet, Lucienne Michaux, Nathalie Nadal, Helene A. Poirel, Isabelle Radford-Weiss, Benedicte Ribourtout, Steven Richebourg, Stephanie Struski, Christine Terre, Isabelle Tigaud, Dominique Penther, Virginie Eclache, Michaela Fontenay, Cyril Broccardo, Eric Delabesse
Summary: This study investigated 113 cases of MDS and MDS/MPN with del(11q), revealing clinical features such as female predominance, similar survival prognosis to other MDS, low monocyte count, and abnormal megakaryopoiesis. The study also identified the common deleted region at 11q23.2, which is located between CADM1 and NXPE2 genes.
Article
Hematology
Shingo Nakahata, Syahrul Chilmi, Ayako Nakatake, Kuniyo Sakamoto, Maki Yoshihama, Ichiro Nishikata, Yoshinori Ukai, Tadashi Matsuura, Takuro Kameda, Kotaro Shide, Yoko Kubuki, Tomonori Hidaka, Akira Kitanaka, Akihiko Ito, Shigeki Takemoto, Nobuaki Nakano, Masumichi Saito, Masako Iwanaga, Yasuko Sagara, Kosuke Mochida, Masahiro Amano, Kouichi Maeda, Eisaburo Sueoka, Akihiko Okayama, Atae Utsunomiya, Kazuya Shimoda, Toshiki Watanabe, Kazuhiro Morishita
Summary: This study demonstrated that plasma sCADM1 concentrations gradually increased during disease progression from indolent to aggressive ATLL, and sCADM1 was identified as a specific biomarker for aggressive ATLL. sCADM1 is not only useful for monitoring response to chemotherapy and predicting relapse of ATLL, but also for distinguishing between ATLL and other inflammatory diseases such as HAM/TSP.
Article
Pharmacology & Pharmacy
Mahek Sharan, Meenakshi Jha, Rishima Chandel, Saima Syeda, Runjhun Mathur, Niraj Kumar Jha, Saurabh Kumar Jha, Harsh Goel, Anju Shrivastava, Sushma Chauhan, Sudheer Pamidimarri, Abhimanyu Kumar Jha
Summary: Cervical cancer is a leading cause of mortality in women in developing countries, with hyper-methylation of tumor suppressor genes through HPV infection being a major cause. In this study, capsaicin was found to have an inhibitory effect on DNMT1 and could reverse the aberrant methylation of CADM1 and SOCS1 genes.
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Astrid K. Laut, Carmen Dorneburg, Axel Furstberger, Thomas F. E. Barth, Hans A. Kestler, Klaus-Michael Debatin, Christian Beltinger
Summary: CHD5, a tumor suppressor located at 1p36, is frequently lost or silenced in aggressive neuroblastoma and many adult cancers. Low expression of CHD5 is associated with stage 4 neuroblastoma and its forced expression inhibits key aspects of the metastatic cascade in vitro. Overexpression of CHD5 leads to reduced metastasis-related genes and gene sets, while known metastasis-suppressing genes are upregulated. Additionally, knockdown of PLCL1 and p53 reverses CHD5-induced inhibition of invasion and migration in vitro.
Article
Oncology
Zhiwei Dong, Kok Siong Yeo, Gonzalo Lopez, Cheng Zhang, Erin N. Dankert Eggum, Jo Lynne Rokita, Choong Yong Ung, Taylor M. Levee, Zuag Paj Her, Cassie J. Howe, Xiaonan Hou, Janine H. van Ree, Shuai Li, Shuning He, Ting Tao, Karen Fritchie, Jorge Torres-Mora, Julia S. Lehman, Alexander Meves, Gina L. Razidlo, Komal S. Rathi, S. John Weroha, A. Thomas Look, Jan M. van Deursen, Hu Li, Jennifer J. Westendorf, John M. Maris, Shizhen Zhu
Summary: Research has shown that GAS7 gene is preferentially deleted in high-risk MYCN-driven neuroblastoma, and its deficiency accelerates metastasis in neuroblastoma models. Loss of GAS7 affects cell-cell interaction and contact among tumor cells, identifying a novel mechanism underlying tumor metastasis in MYCN-driven neuroblastoma.
Review
Oncology
Jennifer Frosch, Ilia Leontari, John Anderson
Summary: Neuroblastoma, a childhood solid cancer, is characterized by resistance to treatment and poor prognosis. Immunotherapeutic approaches targeting myeloid cells show potential, but clinical trials have not replicated preclinical results. Suppressive myeloid cells in the tumor microenvironment play a crucial role in inhibiting antitumor immune responses, correlating with aggressive disease, treatment resistance, and poor prognosis.
Article
Oncology
Hasan Onur Caglar
Summary: This study aimed to identify potential tumor suppressor genes within commonly deleted regions in neuroblastoma tumors and explore the interaction network of proteins encoded by genes in these regions. The results showed that the selected genes in the deletion regions were downregulated and the hub genes identified may act as tumor suppressors in neuroblastoma tumorigenesis.
Article
Oncology
Ana Costa, Cecile Thirant, Amira Kramdi, Cecile Pierre-Eugene, Caroline Louis-Brennetot, Orphee Blanchard, Didier Surdez, Nadege Gruel, Eve Lapouble, Gaelle Pierron, Deborah Sitbon, Herve Brisse, Arnaud Gauthier, Paul Freneaux, Mylene Bohec, Virginie Raynal, Sylvain Baulande, Renaud Leclere, Gabriel Champenois, Andre Nicolas, Didier Meseure, Angela Bellini, Aurelien Marabelle, Birgit Geoerger, Fatima Mechta-Grigoriou, Gudrun Schleiermacher, Laurie Menger, Olivier Delattre, Isabelle Janoueix-Lerosey
Summary: This study reveals that the immunocompromised microenvironment of neuroblastoma tumors is characterized by dysfunctional T cells and accumulation of immunosuppressive cells. The study provides a new and valuable data resource to better understand the neuroblastoma ecosystem and suggests novel therapeutic strategies targeting both tumor cells and components of the microenvironment.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Cell Biology
Christine Engelmann, Patrick Schuhmachers, Hana Zdimerova, Sanamjeet Virdi, Mathias Hauri-Hohl, Jana Pachlopnik Schmid, Adam Grundhoff, Rebecca A. Marsh, Wendy Wei-Lynn Wong, Christian Muenz
Summary: XLP is caused by loss of SAP or XIAP. Inhibition of XIAP leads to loss of B cells and decrease in viral titers and lymphomagenesis in humanized mice. Memory B cell loss is also observed in patients with XIAP deficiency.
CELL DEATH & DISEASE
(2022)
Article
Oncology
Marzia Ognibene, Patrizia De Marco, Loredana Amoroso, Davide Cangelosi, Federico Zara, Stefano Parodi, Annalisa Pezzolo
Summary: Neuroblastoma (NB), a tumor affecting the peripheral sympathetic nervous system, has unknown mechanisms determining its progression. This study found that loss of chromosome 10q is associated with poor prognosis in NB patients. Additionally, it identified a cluster of 75 deleted genes, including CCSER2, whose low expression is correlated with worse survival.
Article
Oncology
Chik Hong Kuick, Jia Ying Tan, Deborah Jasmine, Tohari Sumanty, Alvin Y. J. Ng, Byrrappa Venkatesh, Huiyi Chen, Eva Loh, Sudhanshi Jain, Wan Yi Seow, Eileen H. Q. Ng, Derrick W. Q. Lian, Shui Yen Soh, Kenneth T. E. Chang, Zhi Xiong Chen, Amos H. P. Loh
Summary: Our study found that mutations in chromosome 1 genes are common in 1p-intact neuroblastoma, but may not always disrupt the function of authentic 1p tumor suppressors. These findings suggest a complex interplay of 1p gene aberrations contributing to tumor suppressor inactivation in neuroblastoma.
Article
Medicine, General & Internal
Wei-Li Xu, Bao-Jun Shi, Suo-Lin Li, Feng-Xue Yu, Li-Na Guo, Meng Li, Zhi-Gang Hu, Gui-Xin Li, Hui Zhou
Summary: The study demonstrated that low-dose doxorubicin can enhance the efficacy of immunotherapy in neuroblastoma by selectively inhibiting MDSCs, promoting immune function, and inhibiting tumor growth.
CHINESE MEDICAL JOURNAL
(2021)
Article
Biochemistry & Molecular Biology
Zhangjie Wang, Na Shen, Ziao Wang, Lei Yu, Song Yang, Yang Wang, Yu Liu, Gaohua Han, Qi Zhang
Summary: This study reveals that TRIM3 functions as a tumor suppressor in non-small cell lung cancer (NSCLC) by promoting cell death and inhibiting tumorigenesis. TRIM3 directly interacts with SLC7A11/xCT, leading to its degradation and inhibition of NSCLC development. Low TRIM3 expression is associated with a worse prognosis in NSCLC.
CELL DEATH AND DIFFERENTIATION
(2023)
Article
Biochemical Research Methods
Chen Hong, Robin Thiele, Lars Feuerbach
Summary: Analyzing focal copy number variations (CNVs) is crucial for cancer research as it helps identify driver genes. We have developed the GenomeTornadoPlot software package that provides visualizations of CNV types, locations, and lengths, and allows for gene-to-gene comparisons to identify co-mutation patterns or driver-passenger gene hierarchies.
Article
Biotechnology & Applied Microbiology
Holly Holliday, Jessica Yang, Eoin Dodson, Iva Nikolic, Alvin Kamili, Madeleine Wheatley, Niantao Deng, Sarah Alexandrou, Thomas P. Davis, Maria Kavallaris, C. Elizabeth Caldon, Joshua McCarroll, Katleen De Preter, Pieter Mestdagh, Glenn M. Marshall, Kaylene J. Simpson, Jamie Fletcher, Alexander Swarbrick
Summary: This study discovered that miR-99b-5p, miR-380-3p, and miR-485-3p enhance the chemotherapeutic effects of doxorubicin in high-risk neuroblastoma. These miRNAs are often lost in patients and their low expression predicts poor survival outcomes.
Article
Multidisciplinary Sciences
Yuya Terashima, Etsuko Toda, Meiji Itakura, Mikiya Otsuji, Sosuke Yoshinaga, Kazuhiro Okumura, Francis H. W. Shand, Yoshihiro Komohara, Mitsuhiro Takeda, Kana Kokubo, Ming-Chen Chen, Sana Yokoi, Hirofumi Rokutan, Yutaka Kofuku, Koji Ohnishi, Miki Ohira, Toshihiko Iizasa, Hirofumi Nakano, Takayoshi Okabe, Hirotatsu Kojima, Akira Shimizu, Shiro Kanegasaki, Ming-Rong Zhang, Ichio Shimada, Hiroki Nagase, Hiroaki Terasawa, Kouji Matsushima
NATURE COMMUNICATIONS
(2020)
Article
Biochemistry & Molecular Biology
Yohko Yamaguchi, Kohei Kaida, Yusuke Suenaga, Akihito Ishigami, Yoshiro Kobayashi, Kisaburo Nagata
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
(2020)
Correction
Oncology
Tomoro Hishiki, Kimikazu Matsumoto, Miki Ohira, Takehiko Kamijo, Hiroyuki Shichino, Tatsuo Kuroda, Akihiro Yoneda, Toshinori Soejima, Atsuko Nakazawa, Tetsuya Takimoto, Isao Yokota, Satoshi Teramukai, Hideto Takahashi, Takashi Fukushima, Takashi Kaneko, Junichi Hara, Michio Kaneko, Hitoshi Ikeda, Tatsuro Tajiri, Akira Nakagawara
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY
(2020)
Article
Oncology
Kiyohiro Ando, Verna Cazares-Ordonez, Makoto Makishima, Atsushi Yokoyama, Yusuke Suenaga, Hiroki Nagase, Shinichi Kobayashi, Takehiko Kamijo, Tsugumichi Koshinaga, Satoshi Wada
JOURNAL OF ONCOLOGY
(2020)
Article
Oncology
Shintaro Iwata, Yasutoshi Tatsumi, Tsukasa Yonemoto, Akinobu Araki, Makiko Itami, Hiroto Kamoda, Toshinori Tsukanishi, Yoko Hagiwara, Hideyuki Kinoshita, Takeshi Ishii, Hiroki Nagase, Miki Ohira
Summary: The study identified CDK4 overexpression and amplification in tumors as predictive biomarkers for resistance to conventional chemotherapy in patients with OS, and palbociclib as a promising drug for this therapeutically challenging cohort.
Article
Oncology
Tatsuhito Matsuo, Kazuma Nakatani, Taiki Setoguchi, Koichi Matsuo, Taro Tamada, Yusuke Suenaga
Summary: NCYM, a newly evolved gene from non-genic regions specific to Homininae, has been shown to promote human tumor aggressiveness. The secondary structure of NCYM was determined using vacuum-ultraviolet circular dichroism, revealing that the Homininae-specific domain is responsible for MYCN stabilization. This study provides insights into the oncogenic functions of NCYM and potential strategies for cancer therapy.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Kiyohiro Ando, Miki Ohira, Ichiro Takada, Verna Cazares-Ordonez, Yusuke Suenaga, Hiroki Nagase, Shinichi Kobayashi, Tsugumichi Koshinaga, Takehiko Kamijo, Makoto Makishima, Satoshi Wada
Summary: This study identified a potential mechanism of resistance to CHK1 inhibitors in neuroblastoma cells, involving altered expression of FGFR2 and reactivation of the MEK/ERK signaling pathway. Targeting both CHK1 and MEK1/2 could be a promising treatment strategy for MYCN-amplified neuroblastomas.
Article
Oncology
Jesmin Akter, Yutaka Katai, Parvin Sultana, Hisanori Takenobu, Masayuki Haruta, Ryuichi P. Sugino, Kyosuke Mukae, Shunpei Satoh, Tomoko Wada, Miki Ohira, Kiyohiro Ando, Takehiko Kamijo
Summary: Genetic aberrations in the ATRX gene are associated with poor clinical outcomes in older high-risk neuroblastoma patients. Loss of ATRX function contributes to telomere lengthening and is linked to DNA damage through G-quadruplex structures. Knocking out ATRX in different neuroblastoma cell lines revealed that ATRX deficiency leads to increased DNA damage and activation of the ATM/CHK2/p53 pathway in wild-type TP53 cells, while the effect is less pronounced in TP53-truncated cells.
Editorial Material
Oncology
Yusuke Suenaga, Christer Einvik, Atsushi Takatori, Yuyan Zhu
FRONTIERS IN ONCOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Miki Ohira, Yohko Nakamura, Tetsuya Takimoto, Atsuko Nakazawa, Tomoro Hishiki, Kimikazu Matsumoto, Hiroyuki Shichino, Tomoko Iehara, Hiroki Nagase, Takashi Fukushima, Akihiro Yoneda, Tatsuro Tajiri, Akira Nakagawara, Takehiko Kamijo
Summary: This study validates the clinical relevance of International Neuroblastoma Risk Group (INRG) prognostic and genomic markers in a Japanese neuroblastoma cohort. The results show that age, tumor stage, MYCN, DNA ploidy, and other factors are associated with lower survival rates, while certain chromosome aberrations and primary tumor site are associated with a favorable prognosis. In patients with MYCN non-amplified tumors, age, LDH, and chromosome breakpoints are correlated with lower survival rates. The study suggests that combining tumor genomic pattern with age and LDH could be a promising predictor for high-risk neuroblastomas.
Article
Biochemistry & Molecular Biology
Yusuke Suenaga, Mamoru Kato, Momoko Nagai, Kazuma Nakatani, Hiroyuki Kogashi, Miho Kobatake, Takashi Makino
Summary: Recent studies have discovered numerous RNAs with coding and noncoding functions, but the sequence characteristics that determine this bifunctionality are still unknown. This study introduces and tests the ORF dominance score, which measures the fraction of the longest ORF in all potential ORF lengths. The score is found to correlate with translation efficiency in coding transcripts and noncoding RNAs. In eukaryotes, there is a significant overlap in ORF dominance between coding and noncoding transcripts, while bacteria and archaea have distinct distributions. Tissue-specific transcripts tend to have higher ORF dominance, particularly those expressed in mature testes. These findings suggest that the evolution of potentially bifunctional RNAs in eukaryotic organisms may have been facilitated by a decrease in population size and the emergence of testes.
Article
Oncology
Kyosuke Mukae, Hisanori Takenobu, Yuki Endo, Masayuki Haruta, Tianyuan Shi, Shunpei Satoh, Miki Ohira, Michinori Funato, Junya Toguchida, Kenji Osafune, Tatsutoshi Nakahata, Hiroaki Kanda, Takehiko Kamijo
Summary: In this study, an in vitro tumorigenesis model of chondroblastic osteosarcoma was successfully established using hiPSC-derived neural crest cells overexpressing MYCN and with a heterozygous TP53 hotspot mutation. Suppression of MYCN decreased the proliferation of MYCN-induced osteosarcoma cells, indicating MYCN as a potential target for a subset of osteosarcoma treatment. Comprehensive gene expression analysis and exome sequencing revealed osteosarcoma-specific molecular features, including activation of TGF-beta signaling and DNA copy number amplification of GLI1. This study provides a useful tool for the development of new tumor models using gene-modified hiPSC-derived progenitor cells.
Article
Biochemistry & Molecular Biology
Kiyohiro Ando, Yusuke Suenaga, Takehiko Kamijo
Summary: Identifying the vulnerability of altered DNA repair machinery that displays synthetic lethality with MYCN amplification is a therapeutic rationale in unfavourable neuroblastoma. However, none of the inhibitors for DNA repair proteins are established as standard therapy in neuroblastoma. DNA-PK inhibitor (DNA-PKi) showed inhibitory effects on the proliferation of MYCN-driven neuroblastoma spheroids and cell lines. Among them, DNA ligase 4 (LIG4) was identified as a prognostic factor and its inhibition combined with DNA-PKi may overcome resistance to multimodal therapy in MYCN-amplified neuroblastoma.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Oncology
Yusuke Suenaga, Kazuma Nakatani, Akira Nakagawara
JAPANESE JOURNAL OF CLINICAL ONCOLOGY
(2020)